Better Therapeutics Inc (NASDAQ: BTTX) stock fell -0.19% on Monday to $0.21 against a previous-day closing price of $0.21. With 1.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.72 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.2096 whereas the lowest price it dropped to was $0.1857. The 52-week range on BTTX shows that it touched its highest point at $1.61 and its lowest point at $0.14 during that stretch. It currently has a 1-year price target of $5.25. Beta for the stock currently stands at 2.55.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BTTX was up-trending over the past week, with a rise of 28.98%, but this was down by -0.19% over a month. Three-month performance dropped to -66.53% while six-month performance fell -73.43%. The stock lost -85.03% in the past year, while it has lost -81.03% so far this year. A look at the trailing 12-month EPS for BTTX yields -1.16 with Next year EPS estimates of -0.78. For the next quarter, that number is -0.13. This implies an EPS growth rate of 50.59% for this year and 6.59% for next year.
Float and Shares Shorts:
At present, 23.85 million BTTX shares are outstanding with a float of 23.31 million shares on hand for trading. On Oct 30, 2023, short shares totaled 1.59 million, which was 3.91% higher than short shares on Sep 28, 2023. In addition to Mr. David P. Perry M.B.A. as the firm’s Co-Founder & Executive Chairman, Mr. Frank L. Karbe serves as its CEO, President & Director.
Through their ownership of 4.59% of BTTX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 47.95% of BTTX, in contrast to 3.97% held by mutual funds. Shares owned by individuals account for 1.34%. As the largest shareholder in BTTX with 3.34% of the stake, MM Asset Management, Inc. holds 1,583,079 shares worth 1,583,079. A second-largest stockholder of BTTX, The Vanguard Group, Inc., holds 499,897 shares, controlling over 1.06% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in BTTX, holding 106,878 shares or 0.23% stake. With a 0.69% stake in BTTX, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 326,043 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.37% of BTTX stock, is the second-largest Mutual Fund holder. It holds 173,854 shares valued at 24687.0. Fidelity Extended Market Index Fu holds 0.18% of the stake in BTTX, owning 83,623 shares worth 11874.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BTTX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BTTX analysts setting a high price target of $9.00 and a low target of $1.50, the average target price over the next 12 months is $5.25. Based on these targets, BTTX could surge 4185.71% to reach the target high and rise by 614.29% to reach the target low. Reaching the average price target will result in a growth of 2400.0% from current levels.
Summary of Insider Activity:
Insiders traded BTTX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 17 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 8,513,323 while 0 shares were sold.